Healthy Volunteers - Male and FemaleNCT07305532
¹⁹F (Perfluoropropane) MRI
A study testing 19F(perfluoropropane) MRI in people with Healthy Volunteers - Male and Female, run by Alexei Ouriadov at 1 site in Canada.
Trial summary
Healthy volunteers aged 18 to 85 will undergo ¹⁹F (perfluoropropane) MRI to support the development of imaging sequences, reconstruction algorithms, and hardware necessary for acquiring high-spatial resolution lung images. Read more about this study
- Who is it for?
- Ages 18 to 85 yearsHealthy volunteers can take part
- Conditions the study is for
- Healthy Volunteers - Male and Female
- What is being tested?
- 19F(perfluoropropane) MRI
- Type of treatment
- Medical device
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 200 participants
- Where
- 1 siteCanada
- Study dates
- 20 May 2026to 30 Dec 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 85 years
- All sexes
- Healthy volunteers accepted
- Adult, Older adult
Who may be able to join
- Participants eligible for inclusion in this study must meet all of the following criteria:
- Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.
- Provision of written, informed consent prior to any study specific procedures.
- Males and females aged 18 to 85 years.
- Participant must be able to perform a breath-hold for 16s.
- Participant has a BMI between 18 and 40
- Participant must be able to perform reproducible pulmonary function tests (i.e., the 3 best acceptable spirograms have forced expiratory volume in 1 second (FEV1) and forced vital capacity (FVC) values that do not vary more than 5% of the largest value or more than 100 ml, whichever is greater)
- Participants are judged to be in stable health on the basis of medical history
Who cannot join
- Participants fulfilling any of the following criteria are not eligible for inclusion in this study:
- Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).
- In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.
- Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.
- Participant is unable to perform spirometry maneuvers.
- Participant is unable to perform MRI and CT breath-hold maneuvers.
Show all 10Show fewer
- Participant has a history of chronic or acute respiratory disease
- FEV1 <70%
- Participant has a history of cardiovascular disorders including coronary insufficiency, cardiac arrhythmias, severe hypertension (≥160 over ≥100)
- Participant has a daytime room air oxygen saturation ≤ 92% ± 2% while supine
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Tommy Li, Msc contact
Canada1 site
St Joseph's Healthcare London
London, Ontario, N6A 4V2
Hana Serajeddini, MD, FRCPC, 519) 646-6100 ext. 66288, hana.serajeddini@lhsc.on.ca
Tommy Li, zli3569@uwo.ca
About this study
Official title: HARDWARE AND SOFTWARE DEVELOPMENT FOR PULMONARY MAGNETIC RESONANCE IMAGING USING INHALED INERT FLOURINATED GAS
Healthy volunteers aged 18 to 85 will undergo ¹⁹F (perfluoropropane) MRI to support the development of imaging sequences, reconstruction algorithms, and hardware necessary for acquiring high-spatial resolution lung images. The study will also evaluate signal-to-noise ratio, contrast-to-noise ratio, spatial resolution, scan duration, and pulmonary gas exchange measurements derived from ¹⁹F (perfluoropropane) MRI.
Read the detailed description
Briefly, during this two-hour visit, participants will provide written informed consent and then undergo:
- Brief medical history and vital signs,
- Full pulmonary function tests,
- Proton MRI,
- 19F(perfluoropropane) MRI, As part of the MRI, participants will inhale or 19F gas as a contrast agent to assess lung ventilation Spirometry will be performed at each visit according to American Thoracic Society (ATS) guidelines using MedGraphics Elite Series (MedGraphics Corporation. St. Paul, MN USA) and/or nDD EasyOne Spirometer (nDD Medical Technologies Inc. Andover, MA USA). Fractional exhaled nitric oxide (FeNO) will be measured using the NIOX VERO® (Circassia Pharmaceuticals Inc., Morrisville, NC, USA). All measurements will be performed at St Joseph's Healthcare London.
They will be placed in the 3T PET/MRI scanner with a coil fitted over their torso and chest. Hearing protection will be provided to muffle the noise produced by the 3D imaging gradient coils. A pulse oximeter lead will be used to monitor heart rate and oxygen saturation. MRI will be performed for up to a period of seven to ten minutes. All imaging will be performed in a "breath-hold" fashion. All participants will have supplemental oxygen provided via nasal cannula at a flow rate of at least two liters per minute during the scanning process. Logs and records of gas exposure will be maintained for every volunteer in this study.
- Conditions
- Healthy Volunteers - Male and Female
- Being tested
- 19F(perfluoropropane) MRI
- Keywords
- 19F(perfluoropropane) MRI
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
19F(perfluoropropane) MRIDevice
19F(perfluoropropane) MRI is an emerging technique for imaging lung ventilation using inhaled, inert fluorinated gas. In contrast to proton-based MRI imaging, perfluoropropane gas is used as a contrast agent to directly visualize the airways, and thus ventilation. In this study, we aim to develop and evaluate an inert fluorinated gas-based MRI (19F MRI) technique to enhance non-invasive imaging in healthy adults without a history of acute or chronic respiratory disease.
| Study group | Role | What they receive |
|---|---|---|
| ¹⁹F (perfluoropropane) MRI | Experimental | Participants will undergo pulmonary function tests, ¹⁹F (perfluoropropane) MRI at the visit. Receives: Device: 19F(perfluoropropane) MRI |
What is being measured
The primary outcome is the main question the study is designed to answer.
Image spatial resolution
The primary endpoints are to assess the necessary imaging sequences, reconstruction algorithms, and hardware to acquire high spatial resolution lung images from MRI. Image spatial resolution (mm) is the ability of the imaging system to distinguish small structures, expressed as the smallest detectable detail in millimeters. Higher spatial resolution (smaller values) allows finer anatomical detail to be visualized.
Measured: 5 years
Signal-to-noise ratio (SNR)
A quantitative measure of image quality that compares the level of the desired signal to the background noise in an MRI image. Higher SNR values indicate clearer images with less noise, allowing for better visualization of anatomical structures.
Measured: 5 years
Contrast-to-noise ratio (CNR)
A measure of how well different tissues or structures can be distinguished from each other in an image relative to background noise. Higher CNR indicates better contrast and improved visibility of anatomical differences.
Measured: 5 years
Scan duration (minutes)
The total time required to complete the imaging acquisition for the protocol, measured in minutes.
Measured: 5 years
Secondary outcomes (2)
Ventilation Defect Percent (VDP) of the lung
VDP is a widely used noble gas MRI biomarkers that is calculated by normalizing ventilation defect volume to the thoracic cavity.
Measured: 5 years
Fractional Ventilation (r)
Fractional Ventilation (r) is a quantitative imaging biomarker representing the fraction of gas volume in a lung region that is replaced by fresh inhaled air during a single breath. It is calculated using gas magnetic resonance imaging (MRI), where dynamic imaging tracks the wash-in and wash-out of inhaled gases (e.g., 19F (perfluoropropane)) within lung voxels. Fractional ventilation provides a regional measure of pulmonary ventilation efficiency and heterogeneity.
Measured: 5 years
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Dec 2025
- Study start20 May 2026 (estimated)
- Primary completion30 Aug 2030 (estimated)
- Study completion30 Dec 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Healthy Volunteers - Male and FemaleStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Device: ¹⁹F (perfluoropropane) MRI
- Masking
- None (open label)
- Enrolment
- 200 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Alexei Ouriadov
- Sponsor type
- University, hospital or other
- Collaborators
- St. Joseph's Health Care London
- Responsible party
- Sponsor-investigator, Alexei Ouriadov, Western University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07305532
- Sponsor's protocol ID
- SJHCF0001
- Status last verified
- Dec 2025
- First submitted
- 12 Dec 2025
- Last updated
- 22 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided: Deidentified individual participant data supporting the results will be shared beginning 9 months after publication, available for up to 5 years. Access is open to researchers with approved proposals, subject to a data use agreement. Data will be shared via a secure platform upon approval
Study at a glance
From the registry record, last updated by the sponsor on 22 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- HARDWARE AND SOFTWARE DEVELOPMENT FOR PULMONARY MAGNETIC RESONANCE IMAGING USING INHALED INERT FLOURINATED GAS
- ClinicalTrials.gov ID
- NCT07305532
- Acronym / sponsor ID
- SJHCF0001
- Conditions
- Healthy Volunteers - Male and Female
- Keywords
- 19F(perfluoropropane) MRI
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 200 participants (estimated)
- Lead sponsor
- Alexei OuriadovUniversity, hospital or other
- Collaborators
- St. Joseph's Health Care London
- Study start
- 20 May 2026 (estimated)
- Primary completion
- 30 Aug 2030 (estimated)
- Study completion
- 30 Dec 2030 (estimated)
- First posted
- 26 Dec 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Healthy volunteers aged 18 to 85 will undergo ¹⁹F (perfluoropropane) MRI to support the development of imaging sequences, reconstruction algorithms, and hardware necessary for acquiring high-spatial resolution lung images. The study will also evaluate signal-to-noise ratio, contrast-to-noise ratio, spatial resolution, scan duration, and pulmonary gas exchange measurements derived from ¹⁹F (perfluoropropane) MRI.
Detailed description
Briefly, during this two-hour visit, participants will provide written informed consent and then undergo:
- Brief medical history and vital signs,
- Full pulmonary function tests,
- Proton MRI,
- 19F(perfluoropropane) MRI, As part of the MRI, participants will inhale or 19F gas as a contrast agent to assess lung ventilation Spirometry will be performed at each visit according to American Thoracic Society (ATS) guidelines using MedGraphics Elite Series (MedGraphics Corporation. St. Paul, MN USA) and/or nDD EasyOne Spirometer (nDD Medical Technologies Inc. Andover, MA USA). Fractional exhaled nitric oxide (FeNO) will be measured using the NIOX VERO® (Circassia Pharmaceuticals Inc., Morrisville, NC, USA). All measurements will be performed at St Joseph's Healthcare London.
They will be placed in the 3T PET/MRI scanner with a coil fitted over their torso and chest. Hearing protection will be provided to muffle the noise produced by the 3D imaging gradient coils. A pulse oximeter lead will be used to monitor heart rate and oxygen saturation. MRI will be performed for up to a period of seven to ten minutes. All imaging will be performed in a "breath-hold" fashion. All participants will have supplemental oxygen provided via nasal cannula at a flow rate of at least two liters per minute during the scanning process. Logs and records of gas exposure will be maintained for every volunteer in this study.
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Device: ¹⁹F (perfluoropropane) MRI
| Arm | Type | Receives |
|---|---|---|
| ¹⁹F (perfluoropropane) MRI | Experimental | Device: 19F(perfluoropropane) MRIParticipants will undergo pulmonary function tests, ¹⁹F (perfluoropropane) MRI at the visit. |
Who may qualify
- Ages
- 18 to 85 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Participants eligible for inclusion in this study must meet all of the following criteria:
- Patient understands study procedures and is willing to participate in the study as indicated by the patient's signature.
- Provision of written, informed consent prior to any study specific procedures.
- Males and females aged 18 to 85 years.
- Participant must be able to perform a breath-hold for 16s.
Key exclusion criteria (10 listed)
- Participants fulfilling any of the following criteria are not eligible for inclusion in this study:
- Patient has an MR incompatible implanted mechanically, electrically, or magnetically activated device or any metal in their body which cannot be removed, including but not limited to pacemakers, neurostimulators, biostimulators, implanted insulin pumps, aneurysm clips, bioprosthesis, artificial limb, metallic fragment or foreign body, shunt, surgical staples (including clips or metallic sutures and/or ear implants) (at the discretion of the MRI Technologist).
- In the investigator's opinion, subject suffers from any physical, psychological or other condition(s) that might prevent performance of the MRI or CT, such as severe claustrophobia.
- Participants who are pregnant, breastfeeding or have a positive pregnancy test at initial screening visit.
- Participant is unable to perform spirometry maneuvers.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| 19F(perfluoropropane) MRI19F(perfluoropropane) MRI is an emerging technique for imaging lung ventilation using inhaled, inert fluorinated gas. In contrast to proton-based MRI imaging, perfluoropropane gas is used as a contrast agent to directly visualize the airways, and thus ventilation. In this study, we aim to develop and evaluate an inert fluorinated gas-based MRI (19F MRI) technique to enhance non-invasive imaging in healthy adults without a history of acute or chronic respiratory disease. | Device | ¹⁹F (perfluoropropane) MRI |
Primary outcome
Image spatial resolution
Time frame: 5 years
The primary endpoints are to assess the necessary imaging sequences, reconstruction algorithms, and hardware to acquire high spatial resolution lung images from MRI. Image spatial resolution (mm) is the ability of the imaging system to distinguish small structures, expressed as the smallest detectable detail in millimeters. Higher spatial resolution (smaller values) allows finer anatomical detail to be visualized.
Signal-to-noise ratio (SNR)
Time frame: 5 years
A quantitative measure of image quality that compares the level of the desired signal to the background noise in an MRI image. Higher SNR values indicate clearer images with less noise, allowing for better visualization of anatomical structures.
Contrast-to-noise ratio (CNR)
Time frame: 5 years
A measure of how well different tissues or structures can be distinguished from each other in an image relative to background noise. Higher CNR indicates better contrast and improved visibility of anatomical differences.
Scan duration (minutes)
Time frame: 5 years
The total time required to complete the imaging acquisition for the protocol, measured in minutes.
2 secondary outcomes
Ventilation Defect Percent (VDP) of the lung
Time frame: 5 years
Fractional Ventilation (r)
Time frame: 5 years
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 22 Apr 2026.
- Individual participant dataSharing planned: Undecided. Deidentified individual participant data supporting the results will be shared beginning 9 months after publication, available for up to 5 years. Access is open to researchers with approved proposals, subject to a data use agreement. Data will be shared via a secure platform upon approval
Related trials for Healthy Volunteers - Male and Female
Not yet recruitingPhase 2
Effects of Meal Macronutrients on Postprandial Lipids
Nephrotic Syndrome, Lipodystrophy
RecruitingPhase 1
Study to Assess the Plasma Concentration of Rilzabrutinib Given as a Tablet to Adult Participants With Severe Renal Impairment Compared to Matched Participants With Normal Renal Function
Renal Impairment, Healthy Volunteers
Active, not recruitingPhase 1
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Food Effect of JZP047 in Healthy Participants
Healthy Participants
Not yet recruitingObservational study
MENA/Levant Epidemiological, Registry of Immunological & Clinical Traits (MERIT)
Antiphospholipid (aPL)-Positive, Rheumatic Arthritis
RecruitingObservational study
Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue
Bladder Cancer, Urinary Tract Cancer
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Tommy Li, Msc contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing 19F(perfluoropropane) MRI in people with Healthy Volunteers - Male and Female, run by Alexei Ouriadov at 1 site in Canada.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 10 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 22 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Canada. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Hana Serajeddini, MD, FRCPC ((519) 646-6100 ext. 66288, hana.serajeddini@lhsc.on.ca), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Image spatial resolution (time frame: 5 years). The study lists 4 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 22 Apr 2026.